Predicting Follicular NHL Aggressiveness
Scientists at the US National Cancer Institute (NCI) have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis. The model is based on two sets of genes, called survival-associated signatures, whose activity was found to be associated with good or poor prognosis for patients with the cancer. The scientists' results suggest that immune cells infiltrating follicular lymphoma tumors have an important impact on survival; both signatures came from such immune cells.
The growth rate of follicular lymphoma, the most common non-Hodgkin's lymphoma, varies widely. "In some patients the disease progresses slowly over many years, whereas in others progression is rapid, with the cancer transforming into aggressive lymphoma and leading to early death" explained principle investigator Louis M. Staudt, M.D., Ph.D.
You can read more in the November 19, 2004, New England Journal of Medicine
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
